Welcome to our dedicated page for Dynavax Technolo news (Ticker: DVAX), a resource for investors and traders seeking the latest updates and insights on Dynavax Technolo stock.
Dynavax Technologies Corporation (Nasdaq: DVAX) generates a steady flow of news as a commercial-stage biopharmaceutical company focused on vaccines for infectious diseases. News coverage commonly highlights developments related to its adult hepatitis B vaccine HEPLISAV-B®, its CpG 1018® adjuvant platform, and a growing pipeline of adjuvanted vaccine candidates.
Investors and observers following DVAX news will see regular updates on financial results, including quarterly earnings releases filed via Form 8-K, where Dynavax reports HEPLISAV-B net product revenue, total revenues, and adjusted EBITDA, along with commentary on market share trends in the U.S. adult hepatitis B vaccine market. These releases often include forward-looking guidance and discussion of capital allocation decisions such as share repurchase authorizations.
Another major category of Dynavax news involves clinical and pipeline milestones. The company issues press releases on topline data from its Phase 1/2 shingles vaccine trial for Z-1018, describing immunogenicity, tolerability and head-to-head comparisons with Shingrix®. Additional updates cover progress in its plague vaccine program funded by the U.S. Department of Defense, its pandemic influenza adjuvant program using CpG 1018 with H5N1 influenza vaccine, and its investigational Lyme disease vaccine candidate.
Corporate and strategic news items include participation in healthcare investor conferences, announcements of conference calls and webcasts, and collaboration agreements. Notably, Dynavax and Vaxart announced an exclusive license and collaboration for an investigational oral COVID-19 vaccine candidate, and Sanofi has announced an agreement to acquire Dynavax through a cash tender offer and subsequent merger, subject to customary conditions.
By tracking the DVAX news feed, readers can monitor how Dynavax’s commercial performance, clinical data, collaborations and corporate transactions evolve over time. This page aggregates company press releases and related disclosures so that users can review financial updates, pipeline progress and strategic announcements in one place.
Dynavax Technologies Corporation (Nasdaq: DVAX) has successfully closed its underwritten public offering of 16,100,000 shares at $5.00 per share, generating approximately $80.5 million in gross proceeds. The offering included the underwriters' option to purchase an additional 2,100,000 shares. Proceeds will be utilized to support the commercialization of HEPLISAV-B®, advance its CpG 1018 vaccine platform, and enhance general corporate purposes. The offering was managed by Cowen, Evercore ISI, and William Blair, with a shelf registration statement filed with the SEC.
Dynavax Technologies Corporation (Nasdaq: DVAX) has announced a public offering of 14,000,000 shares at $5.00 each, aiming to raise approximately $70 million. This offering, set to close around May 27, 2020, includes a 30-day option for underwriters to purchase an additional 2,100,000 shares. The funds will support the commercialization of HEPLISAV-B® and advancements in the CpG 1018 vaccine platform, potentially for COVID-19. The offering is conducted under a previously effective shelf registration statement filed with the SEC.
Dynavax Technologies Corporation (Nasdaq: DVAX) announced plans for an underwritten public offering to sell shares of its common stock, with a potential 15% over-allotment option for underwriters. Proceeds are intended to support the commercialization of HEPLISAV-B®, advance the CpG 1018 vaccine platform, and cover general corporate expenses. The offering follows a shelf registration statement effective since April 30, 2020. The company emphasizes that the timing and size of the offering depend on market conditions.
Dynavax Technologies Corporation (DVAX) reported Q1 2020 net product revenue of $10.5 million, up from $5.6 million in Q1 2019, driven by increased sales of HEPLISAV-B, despite COVID-19 challenges. The company achieved a seroprotection rate of 86.4% in preliminary results from a clinical trial for dialysis patients. While total R&D expenses decreased, SG&A expenses rose to $20.9 million. A net loss of $12.6 million was reported, an improvement from $39.7 million in the previous year. Dynavax maintains a strong cash position with $129.5 million as of March 31, 2020.
Summary not available.